Food delivery service DoorDash stepped into the coveted “unicorn” club with its latest $535 million funding round, which values it at $1.4 billion. And CEO Tony Xu wants to make sure the company is “scaling quality as we scale quantity,” Xu told Cheddar. “We’re going to be growing to every zip code in every city in North America. As a result, we have to make sure that we keep focusing on the basics.” DoorDash operates in an increasingly competitive space with brands like Seamless, GrubHub, and UberEats all vying for domination. To stay ahead, Xu says his company focuses on maintaining a variety of merchants. “It starts with offering the broadest selection and offering at the highest quality [with] a consistent level of service.” He pointed out that DoorDash serves 90 percent of the top 100 restaurant brands that offer delivery. “That’s more than all our peers combined.” Going forward, Xu sees DoorDash automating parts of its delivery logistics. “We’ve been working with autonomous delivery systems for about three years now,” said Xu. “It’s really a very difficult problem because you’re talking about solving the first- and last-10-feet problem. So this is going to take some time before it truly develops.” Xu also envisions using DoorDash’s technology to get industries beyond restaurants online. “When you can deliver a burrito hot and deliver ice cream that does not melt, you can deliver just about anything.” But Xu didn’t go into any details of the industries that DoorDash is eyeing next. For the full interview, [click here](https://cheddar.com/videos/doordash-raises-535-million-in-series-d-funding).

Share:
More In Business
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More